search
Back to results

22 G - 25 G SINS Trial for Pancreatic Masses (SINS)

Primary Purpose

Pancreatic Neoplasms

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
EUS-FNA of pancreatic masses
22 gauge needle
25 gauge needle
Sponsored by
AdventHealth
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pancreatic Neoplasms

Eligibility Criteria

19 Years - 89 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreatic mass lesions that require FNA
  2. Age ≥ 19 years

Exclusion Criteria:

  1. Age <19 years
  2. Unable to safely undergo EUS for any reason
  3. Coagulopathy (INR >1.6, Thrombocytopenia with platelet count <80,000/ml)
  4. Unable to provide consent for any reason
  5. Pregnancy (confirmed with Standard of Care urine pregnancy test for all women with child-bearing potential)

Sites / Locations

  • Florida Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

22 gauge with suction

22 gauge without suction

25 gauge with suction

25 gauge without suction

Arm Description

EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.

EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.

EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.

EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.

Outcomes

Primary Outcome Measures

Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.
The use of suction and a larger gauge needle during EUS-FNA is likely to increase the diagnostic yield of cell block. This may in turn translate to improved diagnosis and hence expedite patient management

Secondary Outcome Measures

Diagnostic adequacy of FNA cytology
1. Diagnostic adequacy of FNA cytology samples and comparison between the two needle sizes and the effect of application of suction
Median number of passes to diagnosis
2. Median no. of passes required to obtain diagnostically adequate cytological samples, and comparison between the two needle sizes and suction vs. no suction
Specimen bloodiness
3. Specimen bloodiness and comparison between the two needle sizes and two techniques (with and without suction)
Rate of needle dysfunction
4. Rate of needle dysfunction and technical failure, and comparison between the two needle sizes and two techniques (with and without suction)
Rate of complications
5. Rate of complications following EUS-FNA, and comparison between the two needle sizes and two techniques (with and without suction)

Full Information

First Posted
February 11, 2015
Last Updated
February 12, 2019
Sponsor
AdventHealth
search

1. Study Identification

Unique Protocol Identification Number
NCT02424838
Brief Title
22 G - 25 G SINS Trial for Pancreatic Masses
Acronym
SINS
Official Title
Randomized Trial Examining the Relationship Between Procedural Technique and Specimen Evaluation Methods in Patients Undergoing Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) of Pancreatic Masses
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
July 28, 2014 (Actual)
Primary Completion Date
April 3, 2016 (Actual)
Study Completion Date
September 30, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AdventHealth

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
After patients have been screened and have signed informed consent, they will be taken to the endoscopy suite. Once the decision has been made to proceed with Fine Needle Aspiration (FNA), the subject will be randomized to 1 of 4 groups: 22 gauge (G) needle with suction 25 G needle with suction 22 G needle without suction 25 G needle without suction Follow-up Phone Call Phase: Unit staff will call patients 1 week after the procedure to check if patients had any adverse events from the procedure and this will be recorded onto the dataset.
Detailed Description
All adult patients referred to Florida Hospital for evaluation of a pancreatic mass lesion will be eligible for entry into the study. Patients will be approached at the time of procedural consent for the study. After written informed consent is taken, Endoscopic Ultrasound (EUS) will be performed under conscious sedation. At the time of EUS, patients who require FNA will be randomized to the two needles (22 G or 25 G needles) and to the two techniques (using suction or not using suction). Computer-generated randomization assignments using the block randomization method will be obtained from the statistician prior to study enrollment. These will be placed in sequentially numbered sealed opaque envelopes and opened by the endoscopy nurse immediately after the decision to perform FNA is made. The randomization sequence will specify the needle size to be used and whether or not suction will be applied for FNA. FNA will be performed in the standard fashion using one of the designated needle sizes (using the fanning technique to pass the needle 12-16 times into the lesion) by one of the experienced endosonographers in the unit. The needle stylet will be left in place for the first pass and then removed for subsequent passes. Suction will be applied during aspiration of the mass as dictated by the randomization sequence. First two passes will be performed to obtain tissue sample for cell block analysis. Therefore, the tissue obtained with the first and second passes will be expressed onto a slide and into test tubes for cell block analysis. From the third pass onwards, the aspirate obtained will be examined onsite by the cytopathologist, who will be available to interpret the slides immediately to determine diagnostic adequacy of the sample per standard practice. Once the diagnosis is made and the adequacy of the sample is affirmed by the cytopathologist, the procedure will be stopped and the echoendoscope will be withdrawn from the patient. Total number of passes to obtain a diagnostic cytological aspirate made will be recorded at the time of procedure, as well as the occurrence of needle dysfunction, technical failure, and any immediate complications. The samples taken will be transported to the pathology lab (per standard practice) where the cellular aspirate and cell block samples will be evaluated by the pathologist. 10% of samples from each subgroup (i.e. 22G with suction, 22G without suction, 25G with suction, 25G without suction) will be further analyzed for the presence of molecular markers for malignancy. After the appropriate observations are deemed satisfactory, patients will be discharged as per unit policy. Unit staff will call patients 1 week after the procedure to check if patients had any adverse events from the procedure and this will be recorded onto the dataset.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Neoplasms

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
352 (Actual)

8. Arms, Groups, and Interventions

Arm Title
22 gauge with suction
Arm Type
Active Comparator
Arm Description
EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
Arm Title
22 gauge without suction
Arm Type
Active Comparator
Arm Description
EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
Arm Title
25 gauge with suction
Arm Type
Active Comparator
Arm Description
EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
Arm Title
25 gauge without suction
Arm Type
Active Comparator
Arm Description
EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
Intervention Type
Procedure
Intervention Name(s)
EUS-FNA of pancreatic masses
Intervention Description
EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
Intervention Type
Device
Intervention Name(s)
22 gauge needle
Intervention Type
Device
Intervention Name(s)
25 gauge needle
Primary Outcome Measure Information:
Title
Proportion of diagnostic cell block specimens obtained according to needle size and the use of suction.
Description
The use of suction and a larger gauge needle during EUS-FNA is likely to increase the diagnostic yield of cell block. This may in turn translate to improved diagnosis and hence expedite patient management
Time Frame
7 days (cell block processing in lab)
Secondary Outcome Measure Information:
Title
Diagnostic adequacy of FNA cytology
Description
1. Diagnostic adequacy of FNA cytology samples and comparison between the two needle sizes and the effect of application of suction
Time Frame
24 hours
Title
Median number of passes to diagnosis
Description
2. Median no. of passes required to obtain diagnostically adequate cytological samples, and comparison between the two needle sizes and suction vs. no suction
Time Frame
24 hours
Title
Specimen bloodiness
Description
3. Specimen bloodiness and comparison between the two needle sizes and two techniques (with and without suction)
Time Frame
24 hours
Title
Rate of needle dysfunction
Description
4. Rate of needle dysfunction and technical failure, and comparison between the two needle sizes and two techniques (with and without suction)
Time Frame
24 hours
Title
Rate of complications
Description
5. Rate of complications following EUS-FNA, and comparison between the two needle sizes and two techniques (with and without suction)
Time Frame
3 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All patients referred to Florida Hospital Endoscopy Unit for assessment of pancreatic mass lesions that require FNA Age ≥ 19 years Exclusion Criteria: Age <19 years Unable to safely undergo EUS for any reason Coagulopathy (INR >1.6, Thrombocytopenia with platelet count <80,000/ml) Unable to provide consent for any reason Pregnancy (confirmed with Standard of Care urine pregnancy test for all women with child-bearing potential)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shyam S Varadarajulu, MD
Organizational Affiliation
AdventHealth
Official's Role
Principal Investigator
Facility Information:
Facility Name
Florida Hospital
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to share Individual Participant Data.
Citations:
PubMed Identifier
29535060
Citation
Bang JY, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. Endoscopic Ultrasound-guided Specimen Collection and Evaluation Techniques Affect Diagnostic Accuracy. Clin Gastroenterol Hepatol. 2018 Nov;16(11):1820-1828.e4. doi: 10.1016/j.cgh.2018.03.004. Epub 2018 Mar 11.
Results Reference
derived

Learn more about this trial

22 G - 25 G SINS Trial for Pancreatic Masses

We'll reach out to this number within 24 hrs